DESCRIPTION

Journal of Oncological Science (JOS) is the official journal of Turkish Society of Medical Oncology. JOS is an international multidisciplinary oncology journal, which publishes high quality original research, reviews, short communications (as letters), case reports and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, pediatric oncology, radiation oncology, surgical oncology, therapeutic radiology and cancer epidemiology and prevention.

Papers will be submitted in submission web site. Editorial office will rapidly review papers and those of insufficient quality will be returned to the author 3 weeks, while those with sufficient priority will be passed to external review.

JOS is an online-only, open access, peer-reviewed journal. With a large international editorial board of experts, JOS aims to advance clinically-relevant knowledge of cancer, and improve prevention, diagnosis and treatment of malignant disease. It provides an integrated view of oncology across all disciplines. The emphasis will be on publishing high quality papers rapidly and freely available to researchers worldwide.

JOS is published every 4 months (total of 3 issues per year).

ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)
Turkey Science Citation Index
Index Copernicus

EDITORIAL BOARD

Editor-in-Chief
Hüseyin Abalı, King Hamad Oncology Center Department of Medical Oncology, Acıbadem University, Adana, Turkey

Deputy Editor
Hasan Şenol Coşkun, Faculty of Medicine Department of Medical Oncology, Akdeniz University, Adana, Turkey
Molecular Oncology
Associate Editors
Ahmet Bilici, Faculty of Medicine, Department of Medical Oncology, Unkapanı Medipol University of Istanbul, Istanbul, Turkey
Breast cancer and Gynecological Cancers
İrfan Çiçin, Trakya University Faculty of Medicine, Department of Medical Oncology, Trakya University, Edirne, Turkey
Thoracic and Urinary Cancers
Ahmet Taner Sümbül, Faculty of Medicine, Department of Medical Oncology, Başkent University, Adana, Turkey
Gastrointestinal Cancers, Sarcoma, CNS and Others

Past Editor
Gökhan Demir, Faculty of Medicine Department of Medical Oncology, Acıbadem University, Istanbul, Turkey

Owner on Behalf of the Turkish Society of Medical Oncology
Mahmut Gümiş, Faculty of Medicine Department of Medical Oncology, Istanbul Medeniyet University, Ankara, Turkey

Editorial Board
U. Abacıoğlu, Department of Radiation Oncology, Neolife Medical Center, Istanbul, Turkey
H. Akbulut, Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Turkey
S. Aksoy, Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey
C. Aliyev, National Center of Oncology, Ministry of Health, Azerbaijan
A. Arıcan, Faculty of Medicine Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
B. Arun, Medical Oncology, MD Anderson Cancer Center, USA
I. Athanasiadis, Hematology-Oncology, Mitera Hospital, Athens, Greece
F. Aykan, İstanbul Faculty of Medicine, Department of Medical Oncology, İstanbul University, İstanbul, Turkey
D. Bafuloukos, Medical Oncology, Metropolitan Hospital, Athens, Greece
G. Başaran, Faculty of Medicine, Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
S. Bavbek, Medical Oncologist, İstanbul, Turkey
S. Bazarbashi, Medical Oncology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia
N. Bese, Department of Radiation Oncology, Acıbadem University, İstanbul, Turkey
E. Büyüküna, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul, Turkey
G. Demir, Faculty of Medicine, Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
A. Demirkazık, Faculty of Medicine Department of Medical Oncology, Ankara University, Ankara, Turkey
C. Elbi, Global Clinical Development, Oncology, Bayer HealthCare Pharmaceuticals, Whippany, USA
M. Erman, Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey
R.M. Gaafar, Medical Oncology, Cairo University, Cairo, Egypt
R. Geva, Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
E. Gez, Department of Oncology, Rambam Medical Center, Haifa, Israel
H. Gogas, Medical Oncology, University of Athens, Athens, Greece
E. Gökmen, Faculty of Medicine, Department of Medical Oncology, Ege University, İzmir, Turkey
B. Güllüoğlu, General Surgery, Academic Hospital, İstanbul, Turkey
M. Gümüş, Faculty of Medicine, Department of Medical Oncology, İstanbul Medeniyet University, Ankara, Turkey
M. Hayran, Department of Preventive Oncology, Hacettepe University, Ankara, Turkey
F. İçli, Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Turkey
A. İşikdogan, Faculty of Medicine Department of Medical Oncology, Dicle University, Diyarbakir, Turkey
L. Kabasakal, Cerrahpaşa Faculty of Medicine, Department of Nuclear Medicine, İstanbul University, İstanbul, Turkey
M.A. Kaplan, Faculty of Medicine, Department of Medical Oncology, Dicle University, Diyarbakir, Turkey
B. Karabulut, Faculty of Medicine Department of Medical Oncology, Ege University, İzmir, Turkey
N. Karadurmuş, Department of Medical Oncology, Gülhane Research and Training Hospital, Ankara, Turkey
A. Kerimli, National Center of Oncology, Ministry of Health, Azerbaijan
M. A. Khattak, Nedlands, Australia
O. Khorshid, Department of Medical Oncology, Hematological Malignancies & BMT, NCI, Cairo University, Cairo, Egypt
P. A. Kosmidis, Medical Oncology, Hyegeia Hospital, Tirana, Greece
S. Kumar, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA
A. Lancia, Dept. of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
N.M. Mandel, Faculty of Medicine Department of Medical Oncology, Koç University, İstanbul, Turkey
K. Oberg, Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden
B. Öksüzoğlu, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
H. Onat, Medical Oncology Department, Liv Hospital, İstanbul, Turkey
B. Öz, Cerrahpaşa Faculty of Medicine Department of Pathology, İstanbul University, İstanbul, Turkey
F. Özdemir, Faculty of Medicine, Department of Medical Oncology, Karadeniz Technical University, Trabzon, Turkey
M. Özdoğan, Medical Oncology Department, Medstar Antalya Hospital, Antalya, Turkey
M. Özgüroğlu, Cerrahpaşa Faculty of Medicine Department of Medical Oncology, Istanbul University, Istanbul, Turkey
M. Özkan, Faculty of Medicine Department of Medical Oncology, Erciyes Üniversitesi, Kayseri, Turkey
M. Peeters, Medical Oncology Department, Antwerp University Hospital, Edegem, Belgium
N. Peled, Department of Medical Oncology, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
P.A. Philip, Karmanos Cancer Instit., Detroit, Michigan, USA
A. Rustogi, Department of Radiation Oncology, King Hamad Oncology Center, Muharraq, Bahrain
F. Saatçioğlu, Department of Biosciences, University of Oslo, Oslo, Norway
B. Şahin, Faculty of Medicine, Department of Medical Oncology, Çukurova University, Adana, Turkey
P. Saip, Istanbul Faculty of Medicine, Department of Medical Oncology, Istanbul University, Istanbul, Turkey
V. Scagliotti, Department of Clinical and Biological Sciences, Medical Oncology, University of Turin, Orbassano, Italy
S. Serdengeçti, Cerrahpaşa Faculty of Medicine, Department of Medical Oncology, Istanbul University, Istanbul, Turkey
A. Toker, Department of Cardiovascular Surgery, Istanbul Florence Nightingale Hospital, İstanbul, Turkey
B.O. Uluç, Faculty of Medicine Department of Medical Oncology, Acibadem University, Istanbul, Turkey
N. Üskent, Medical Oncology Department, Anadolu Medical Center, Kocaeli, Turkey
S. Yalçın, Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey
H. Yazıcı, Oncology Institute, Istanbul University, Istanbul, Turkey
I. Yücel, Faculty of Medicine, Department of Medical Oncology, Ondokuz Mayis University, Samsun, Turkey
F. Yumuk, Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey
N. Zengin, Medical Oncology, Ankara Numune Training and Research Hospital, Istanbul, Turkey
GUIDE FOR AUTHORS

INTRODUCTION

Types of paper and Contributions
Being the Official Journal of Turkish Society of Medical Oncology, clinical data to be published will mainly be focused on, but not limited to medical oncology. Papers from surgical oncology, radiation oncology, nuclear medicine, preventive oncology and epidemiology will be welcome. All the pre-clinical data including in vitro and in vivo experiment reports related to science of oncology from genetics, pathology, biochemistry, research on animals and cell lines...

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open Access
Every peer-reviewed research article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. The Turkish Society of Medical Oncology will pay to make the article open access. A CC user license manages the reuse of the article (see https://www.elsevier.com/openaccesslicenses). All articles will be published under the following license:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier Researcher Academy

Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Additional information

PREPARATION

How to Cite

The abbreviated name of Journal of Oncological Sciences is "J Oncol Sci". Please use this abbreviation while citing a publication from the journal. An example for a cited article:


Peer review

This journal operates a double blind review process. All contributions are typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

Double-blind review

This journal uses double-blind review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**LaTeX**
You are recommended to use the Elsevier article class elsarticle.cls to prepare your manuscript and BibTeX to generate your bibliography.
Our LaTeX site has detailed submission instructions, templates and other information.

**Article structure**

**Subdivision - numbered sections**
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

**Introduction**
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**
Results should be clear and concise.

**Discussion**
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

**Conclusions**
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

**Appendices**
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

**Essential title page information**
- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
**Abstract**
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Key Words**
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Keywords selected must be in accordance with Medical Subject Headings (MeSH)**
The selection of key words among Medical Subject Headings (MeSH) ([https://www.nlm.nih.gov/mesh/](https://www.nlm.nih.gov/mesh/)) terms for the "Key Words" of article preparation rules in pdf or online formats in "Guide for Authors" might be added as a suggestion.

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Nomenclature and units**
Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUB: Biochemical Nomenclature and Related Documents for further information.

**Math formulae**
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
Artwork

Electronic artwork

General points

• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference style
Text: Indicate references by (consecutive) superscript arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. For further detail and examples you are referred to the AMA Manual of Style, A Guide for Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.

List: Number the references in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Journal abbreviations source
**AFTER ACCEPTANCE**

*Online proof correction*

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

*Offprints*

The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Authors requiring printed copies of multiple articles may use Elsevier Webshop's 'Create Your Own Book' service to collate multiple articles within a single cover.

**AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com